Outset Medical IncNASDAQ:OM
- LAST PRICE3.9700
- TODAY'S CHANGE (%)0.0650 (1.6645%)
- Bid / Lots3.9600/ 4
- Ask / Lots3.9700/ 2
- Open / Previous Close3.8500 / 3.9050
- Day Range
- 52 Week Range
- Volume247,978
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OM |
|---|---|---|
| 09:32 ET | 12039 | 3.83 |
| 09:34 ET | 3521 | 3.8651 |
| 09:36 ET | 13714 | 3.82 |
| 09:38 ET | 8306 | 3.85 |
| 09:39 ET | 300 | 3.89 |
| 09:41 ET | 652 | 3.8795 |
| 09:43 ET | 2945 | 3.85 |
| 09:45 ET | 200 | 3.84 |
| 09:48 ET | 5750 | 3.784 |
| 09:50 ET | 1766 | 3.805 |
| 09:52 ET | 636 | 3.8 |
| 09:54 ET | 800 | 3.79 |
| 09:56 ET | 1300 | 3.79 |
| 09:57 ET | 5835 | 3.78 |
| 09:59 ET | 472 | 3.77 |
| 10:01 ET | 2802 | 3.73 |
| 10:03 ET | 6213 | 3.665 |
| 10:06 ET | 1900 | 3.665 |
| 10:08 ET | 5499 | 3.665 |
| 10:10 ET | 300 | 3.665 |
| 10:12 ET | 11749 | 3.745 |
| 10:14 ET | 2232 | 3.735 |
| 10:15 ET | 1716 | 3.755 |
| 10:17 ET | 1908 | 3.775 |
| 10:19 ET | 3697 | 3.805 |
| 10:21 ET | 6673 | 3.845 |
| 10:24 ET | 9619 | 3.86 |
| 10:26 ET | 25425 | 3.95 |
| 10:28 ET | 14253 | 3.96 |
| 10:30 ET | 11151 | 3.9888 |
| 10:32 ET | 7055 | 3.98 |
| 10:33 ET | 8743 | 3.955 |
| 10:35 ET | 2738 | 3.9747 |
| 10:37 ET | 1836 | 3.97 |
| 10:39 ET | 2761 | 4.0012 |
| 10:42 ET | 3045 | 4.025 |
| 10:44 ET | 3286 | 3.98 |
| 10:46 ET | 9047 | 3.965 |
| 10:48 ET | 4600 | 3.9601 |
| 10:50 ET | 2338 | 3.97 |
May 8, 2024
Outset Medical Reports First Quarter 2024 Financial Results, from 4:02PM ET on Wednesday May 08, 2024 by Dow Jones
4:02PM ET on Wednesday May 08, 2024 by Dow Jones*DJ Outset Medical 1Q Loss/Shr 78c >OM, from 4:02PM ET on Wednesday May 08, 2024 by Dow Jones
4:02PM ET on Wednesday May 08, 2024 by Dow Jones
May 6, 2024
DJ Outset Medical Shares Rise 56% After FDA Grants Clearance for TabloCart, from 10:38AM ET on Monday May 06, 2024 by Dow Jones
10:38AM ET on Monday May 06, 2024 by Dow JonesOutset Medical's TabloCart with Prefiltration Receives FDA 510(k) Clearance, from 8:00AM ET on Monday May 06, 2024 by Dow Jones
8:00AM ET on Monday May 06, 2024 by Dow Jones
May 1, 2024
Outset Medical to Present at Upcoming Investor Conferences, from 4:30PM ET on Wednesday May 01, 2024 by Dow Jones
4:30PM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Outset Medical Inc | 202.0M | -1.2x | --- |
Harvard Bioscience Inc | 143.3M | -16.2x | --- |
AxoGen Inc | 271.0M | -12.4x | --- |
LifeMD Inc | 329.4M | -10.3x | --- |
Fonar Corp | 103.8M | 10.4x | -15.67% |
Akoya Biosciences Inc | 112.8M | -1.4x | --- |
Company Information
Outset Medical, Inc. is a medical technology company. The Company offers Tablo Hemodialysis System (Tablo), which is a single enterprise solution for hemodialysis, comprised of a compact console with integrated water purification, on-demand dialysate production and advanced software and connectivity capabilities. The Company designed Tablo from the ground up to be a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by virtually anyone. The Tablo system comprises components, which include Tablo Console, Tablo Cartridge and Tablo Data Ecosystem. Tablo Console is a compact, mobile and versatile machine consisting of an integrated water purification, on-demand dialysate production system and touchscreen interface with 3D animations. It also offers various key platforms, such as TabloHub, a customer-facing portal; MyTablo, a patient-facing portal, and TabloDash, an internal data analytics platform.
Contact Information
- Headquarters
- 3052 Orchard DriveSAN JOSE, CA, United States 95134
- Phone
- 971-563-3083
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Leslie Trigg
- Chief Financial Officer
- Nabeel Ahmed
- Senior Vice President - Operations and R&D
- Marc Nash
- Chief Technology Officer
- Jean-Olivier Racine
- General Counsel, Company Secretary
- John Brottem
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $202.0M |
|---|---|
Revenue (TTM) | $125.1M |
Shares Outstanding | 51.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.04 |
EPS | $-3.38 |
Book Value | $2.44 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -130.48% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
